Drug-induced fulminant hepatic failure in pregnancy

被引:8
|
作者
Firoz, Tabassum [1 ]
Webber, Douglas [2 ]
Rowe, Hilary [3 ]
机构
[1] Univ British Columbia, Dept Med, 330 East Columbia St, New Westminster V3L 3LW, BC, Canada
[2] Univ British Columbia, Dept Pathol, Vancouver, BC, Canada
[3] Surrey Mem Hosp, Dept Pharm, Surrey, BC, Canada
关键词
Hepatitis; liver failure; liver dysfunction; drug induced; methyldopa; labetalol;
D O I
10.1177/1753495X15598909
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Liver disease in pregnancy can be classified as predating, co-incidental or unique to pregnancy. Medications are often overlooked as a significant cause of liver disease. We present the case of a 39-year-old patient who presented at 20 weeks with jaundice, elevated liver enzymes, and abnormal liver function progressing eventually to fulminant hepatic failure. The patient was on methyldopa and labetalol from 12 weeks' gestational age. Liver biopsy was consistent with drug-induced liver injury. Both methyldopa and labetalol have been associated with hepatotoxicity including liver failure. This case highlights the importance of including medications as a cause of liver failure in pregnant patients.
引用
收藏
页码:190 / 192
页数:3
相关论文
共 50 条
  • [1] Clinical characteristics and prognostic indicators of drug-induced fulminant hepatic failure
    Ohmori, S
    Shiraki, K
    Inoue, H
    Okano, H
    Yamanaka, T
    Deguchi, M
    Sakai, T
    Takase, K
    Nakano, T
    Tameda, Y
    HEPATO-GASTROENTEROLOGY, 2003, 50 (53) : 1531 - 1534
  • [2] Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden
    Björnsson, E
    Jerlstad, P
    Bergqvist, A
    Olsson, R
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2005, 40 (09) : 1095 - 1101
  • [3] Non-paracetamol drug-induced fulminant hepatic failure among adults in Scotland
    Smith, IDM
    Simpson, KJ
    Garden, OJ
    Wigmore, SJ
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2005, 17 (02) : 161 - 167
  • [4] Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure
    Patel, Suraj J.
    Milwid, Jack M.
    King, Kevin R.
    Bohr, Stefan
    Iracheta-Velle, Arvin
    Li, Matthew
    Vitalo, Antonia
    Parekkadan, Biju
    Jindal, Rohit
    Yarmush, Martin L.
    NATURE BIOTECHNOLOGY, 2012, 30 (02) : 179 - 183
  • [5] Developing a Hepatoprotective Strategy for Preventing Drug-Induced Liver Toxicity and Fulminant Hepatic Failure
    Patel, Suraj J.
    King, Kevin R.
    Bohr, Stefan
    Yarmush, Martin L.
    GASTROENTEROLOGY, 2012, 142 (05) : S941 - S941
  • [6] Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure
    Suraj J Patel
    Jack M Milwid
    Kevin R King
    Stefan Bohr
    Arvin Iracheta-Vellve
    Matthew Li
    Antonia Vitalo
    Biju Parekkadan
    Rohit Jindal
    Martin L Yarmush
    Nature Biotechnology, 2012, 30 : 179 - 183
  • [7] Erratum: Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure
    Suraj J Patel
    Jack M Milwid
    Kevin R King
    Stefan Bohr
    Arvin Iracheta-Velle
    Matthew Li
    Antonia Vitalo
    Biju Parekkadan
    Rohit Jindal
    Martin L Yarmush
    Nature Biotechnology, 2014, 32 : 291 - 291
  • [9] A Case of Fulminant Hepatic Failure in Pregnancy
    Halliday, John
    Lokan, Julie
    Angus, Peter W.
    Gow, Paul
    HEPATOLOGY, 2010, 51 (01) : 341 - 342
  • [10] Predictors for outcome on patients with drug-induced fulminant hepatic failure. Results from the Nordic Transplant Registry
    Bjoro, Kristian
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2006, 41 : 19 - 20